Repeat Interferon Gamma Release Assay Use in US Community Healthcare Organizations

Clicks: 10
ID: 332072
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #270 of 296 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 296 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Interferon gamma release assays (IGRA) are the preferred test for TB infection in the US. IGRAs can fluctuate from positive to negative (reversion), but there is limited information about who does or should receive repeat testing in routine clinical care. Methods We performed a retrospective cohort study of all individuals with a positive IGRA in a US community health organization network (OCHIN). We characterized the frequency and predictors of repeat testing and reversion. We used published recommendations to classify repeat IGRAs as “likely”, “possibly”, and “probably not” indicated, and estimated IGRA over- and under-utilization. Results Among 65,728 individuals with a positive IGRA, 8,978 (13.7%) had >1 subsequent test. Of the 8,174 second tests with full results available for analysis, 6,176 (75.6%) remained positive, 1,904 (23.3%) reverted to negative, and 94 (1.2%) were uninterpretable. Higher initial Ag-Nil value (Ag-Nil 0.70-<1.00 aOR 0.38 [95%CI 0.32, 0.45] and Ag-Nil >1.00 aOR 0.06 [95%CI 0.05, 0.07], vs. Ag-Nil 0.35-<0.7), and birth in a country with elevated TB incidence (vs. birth in a country without elevated TB incidence, aOR 0.59 [95%CI 0.52, 0.67]) were associated with lower odds of reversion. Of all repeat tests, 40.0% were likely indicated, 9.0% were possibly indicated, and 51.0% were probably not indicated. Conclusions Approximately 1 in 7 individuals with positive IGRAs had repeat testing. Most repeat tests were probably not indicated according to our utilization classification, whereas nearly half of individuals without a repeat test may have benefited from one.
Reference Key
openalex_W7221307644 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jeffrey I. Campbell, Meredith B. Brooks, Leonardo R. Martinez, Matthew T. Murrill, Pranay Sinha, Emily Martey, Sophia Giebultowicz, Jenine Dankovchik, Angelica Falkenstein, Rachel L. Epstein, Jonathan M. Bressler, Heather E. Angier, Jessica Elizabeth Haberer, Cynthia A. Tschampl, Charles Robert Horsburgh, Helen Elizabeth Jenkins, Karen Rita Jacobson
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag672
URL
https://doi.org/10.1093/ofid/ofag672
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.